Lack of renal 11 beta-hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice.

BACKGROUND: Glucocorticoid hormones play a major role in fetal organ maturation. Yet, excessive glucocorticoid exposure in utero can result in a variety of detrimental effects, such as growth retardation and increased susceptibility to the development of hypertension. To protect the fetus, maternal...

Full description

Bibliographic Details
Main Authors: Laetitia Martinerie, Eric Pussard, Geri Meduri, Anne-Lise Delezoide, Pascal Boileau, Marc Lombès
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3281096?pdf=render
id doaj-6218c49c82d44fa8b759a6373cf3b1ed
record_format Article
spelling doaj-6218c49c82d44fa8b759a6373cf3b1ed2020-11-25T02:04:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0172e3194910.1371/journal.pone.0031949Lack of renal 11 beta-hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice.Laetitia MartinerieEric PussardGeri MeduriAnne-Lise DelezoidePascal BoileauMarc LombèsBACKGROUND: Glucocorticoid hormones play a major role in fetal organ maturation. Yet, excessive glucocorticoid exposure in utero can result in a variety of detrimental effects, such as growth retardation and increased susceptibility to the development of hypertension. To protect the fetus, maternal glucocorticoids are metabolized into inactive compounds by placental 11beta-hydroxysteroid dehydrogenase type2 (11βHSD2). This enzyme is also expressed in the kidney, where it prevents illicit occupation of the mineralocorticoid receptor by glucocorticoids. We investigated the role of renal 11βHSD2 in the control of neonatal glucocorticoid metabolism in the human and mouse. METHODS: Cortisol (F) and cortisone (E) concentrations were measured in maternal plasma, umbilical cord blood and human newborn urine using HPLC. 11βHSD2 activity was indirectly assessed by comparing the F/E ratio between maternal and neonatal plasma (placental activity) and between plasma and urine in newborns (renal activity). Direct measurement of renal 11βHSD2 activity was subsequently evaluated in mice at various developmental stages. Renal 11βHSD2 mRNA and protein expression were analyzed by quantitative RT-PCR and immunohistochemistry during the perinatal period in both species. RESULTS: We demonstrate that, at variance with placental 11βHSD2 activity, renal 11βHSD2 activity is weak in newborn human and mouse and correlates with low renal mRNA levels and absence of detectable 11βHSD2 protein. CONCLUSIONS: We provide evidence for a weak or absent expression of neonatal renal 11βHSD2 that is conserved among species. This temporal and tissue-specific 11βHSD2 expression could represent a physiological window for glucocorticoid action yet may constitute an important predictive factor for adverse outcomes of glucocorticoid excess through fetal programming.http://europepmc.org/articles/PMC3281096?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Laetitia Martinerie
Eric Pussard
Geri Meduri
Anne-Lise Delezoide
Pascal Boileau
Marc Lombès
spellingShingle Laetitia Martinerie
Eric Pussard
Geri Meduri
Anne-Lise Delezoide
Pascal Boileau
Marc Lombès
Lack of renal 11 beta-hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice.
PLoS ONE
author_facet Laetitia Martinerie
Eric Pussard
Geri Meduri
Anne-Lise Delezoide
Pascal Boileau
Marc Lombès
author_sort Laetitia Martinerie
title Lack of renal 11 beta-hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice.
title_short Lack of renal 11 beta-hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice.
title_full Lack of renal 11 beta-hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice.
title_fullStr Lack of renal 11 beta-hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice.
title_full_unstemmed Lack of renal 11 beta-hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice.
title_sort lack of renal 11 beta-hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description BACKGROUND: Glucocorticoid hormones play a major role in fetal organ maturation. Yet, excessive glucocorticoid exposure in utero can result in a variety of detrimental effects, such as growth retardation and increased susceptibility to the development of hypertension. To protect the fetus, maternal glucocorticoids are metabolized into inactive compounds by placental 11beta-hydroxysteroid dehydrogenase type2 (11βHSD2). This enzyme is also expressed in the kidney, where it prevents illicit occupation of the mineralocorticoid receptor by glucocorticoids. We investigated the role of renal 11βHSD2 in the control of neonatal glucocorticoid metabolism in the human and mouse. METHODS: Cortisol (F) and cortisone (E) concentrations were measured in maternal plasma, umbilical cord blood and human newborn urine using HPLC. 11βHSD2 activity was indirectly assessed by comparing the F/E ratio between maternal and neonatal plasma (placental activity) and between plasma and urine in newborns (renal activity). Direct measurement of renal 11βHSD2 activity was subsequently evaluated in mice at various developmental stages. Renal 11βHSD2 mRNA and protein expression were analyzed by quantitative RT-PCR and immunohistochemistry during the perinatal period in both species. RESULTS: We demonstrate that, at variance with placental 11βHSD2 activity, renal 11βHSD2 activity is weak in newborn human and mouse and correlates with low renal mRNA levels and absence of detectable 11βHSD2 protein. CONCLUSIONS: We provide evidence for a weak or absent expression of neonatal renal 11βHSD2 that is conserved among species. This temporal and tissue-specific 11βHSD2 expression could represent a physiological window for glucocorticoid action yet may constitute an important predictive factor for adverse outcomes of glucocorticoid excess through fetal programming.
url http://europepmc.org/articles/PMC3281096?pdf=render
work_keys_str_mv AT laetitiamartinerie lackofrenal11betahydroxysteroiddehydrogenasetype2atbirthatargetedtemporalwindowforneonatalglucocorticoidactioninhumanandmice
AT ericpussard lackofrenal11betahydroxysteroiddehydrogenasetype2atbirthatargetedtemporalwindowforneonatalglucocorticoidactioninhumanandmice
AT gerimeduri lackofrenal11betahydroxysteroiddehydrogenasetype2atbirthatargetedtemporalwindowforneonatalglucocorticoidactioninhumanandmice
AT annelisedelezoide lackofrenal11betahydroxysteroiddehydrogenasetype2atbirthatargetedtemporalwindowforneonatalglucocorticoidactioninhumanandmice
AT pascalboileau lackofrenal11betahydroxysteroiddehydrogenasetype2atbirthatargetedtemporalwindowforneonatalglucocorticoidactioninhumanandmice
AT marclombes lackofrenal11betahydroxysteroiddehydrogenasetype2atbirthatargetedtemporalwindowforneonatalglucocorticoidactioninhumanandmice
_version_ 1724944902044778496